Close Menu

hepatitis

NEW YORK (GenomeWeb News) – The UK's Medical Research Council has awarded £10.6 million ($17.1 million) to three new multi-partner projects that plan to develop genome-based personalized medicine approaches to treating rheumatoid arthritis, hepatitis, and Gaucher disease.

Dutch gene therapy firm UniQure threw its hat into the RNAi ring this week, announcing that it has picked up non-exclusive access to Benitec Biopharma's proprietary expressed RNAi technology for use with its nascent Huntington's disease program.

Investigators from Arrowhead Research this week published data on a novel strategy of administering a cholesterol-conjugated siRNA payload independently from its delivery vehicle, showing that the co-delivery method can achieve significant gene target knockdown in non-human prima

The primary motivation for PerkinElmer's acquisition of Chinese infectious disease diagnostic firm Shanghai Haoyuan Biotech, announced this week, is to provide the Waltham, Mass.-based firm entrée into the nucleic acid-based blood screening market, company executives said this we

People in the News: Robert Gish

Premium

Arrowhead Research has appointed Robert Gish as the chairman of its newly created hepatitis B clinical advisory board.

Arrowhead Research last week released new preclinical data on its lead drug candidate, the hepatitis B virus treatment ARC-520, reporting that the agent could trigger up to multi-log reductions in the levels of circulating viral antigens, while lowering levels of the virus' repli

Australian expressed RNAi drug developer Benitec this week provided an update to its pipeline, disclosing that it once again expects to have a candidate in phase I testing next year following its recent acquisition of Tacere Therapeutics.

A Cepheid executive today provided investors with an update on the company's molecular diagnostic pipeline, stating that the firm currently has 14 tests in development for its automated GeneXpert platform and that it expects to offer the broadest test menu of any molecular diagno

Expressed RNAi drug developer Benitec Biopharma this week provided an update on its pipeline, stating that its two lead programs in cancer-associated neuropathic pain and drug-resistant lung cancer have fallen behind schedule as the company further optimizes its therapeutic candi

Arrowhead Research said this week that it has begun the final processes required to file an investigational new drug application for its RNAi-based hepatitis B treatment ARC-520, including manufacturing, toxicology studies, and preparation of a pre-IND data package for submission

Pages

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.